Utama › Diabetes Jenis 2 › Oklahoma
Kajian klinikal Diabetes Jenis 2 di Oklahoma
13 kajian untuk Diabetes Jenis 2 sedang mencari peserta di lokasi di Oklahoma.
Bandar di Oklahoma
Teks kajian rasmi (Bahasa Inggeris)
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
- Tekton Research Oklahoma City, Oklahoma City
- South Oklahoma Heart Research Group, Oklahoma City
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07064473A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
- Tekton Research Oklahoma City, Oklahoma City
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07754461A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
- Hightower Clinical, Oklahoma City
- Medical Research International, LLC, Oklahoma City
- Ascension St. John - Jane Phillips Medical Center, Tulsa
Mengambil pesertaSukarelawan sihat dialu-alukan
Umur 55 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06112418A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Oklahoma City
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT07743450A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
- Unity Clinical Research, Oklahoma City
Mengambil pesertaFasa 2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 15 Sep 2026 · NCT07340320A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Lynn Institute of Norman, Norman
- Lynn Health Science Institute, Oklahoma City
- Essential Medical Research, Tulsa
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT07351058A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Alliance for Multispecialty Research, LLC, Norman
Mengambil pesertaFasa 2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 14 Sep 2026 · NCT06897475A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
- Research Site, Oklahoma City
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT07662213AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
- Lynn Institute of Norman, Norman
Mengambil pesertaFasa 3
Umur 45 ke atas · Semua jantina · Dikemas kini 1 Sep 2026 · NCT07797335A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
- Research Site, Norman
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 31 Ogo 2026 · NCT07662109A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
- University of Oklahoma Health Sciences Center, Oklahoma City
Mengambil pesertaFasa 3
Umur 10 hingga 17 · Semua jantina · Dikemas kini 7 Ogo 2026 · NCT06739122DISCOVERY of Risk Factors for Type 2 Diabetes in Youth
- The University of Oklahoma Health Sciences Center, Oklahoma City
Mengambil pesertaKajian pemerhatian
Umur 8 hingga 15 · Semua jantina · Dikemas kini 7 Mei 2026 · NCT06525259Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
- Lynn Health Science Institute - Oklahoma City, Oklahoma City
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Mac 2026 · NCT07282743Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.